TY - GEN AU - Di Leo,Angelo AU - Desmedt,Christine AU - Bartlett,John M S AU - Piette,Fanny AU - Ejlertsen,Bent AU - Pritchard,Kathleen I AU - Larsimont,Denis AU - Poole,Christopher AU - Isola,Jorma AU - Earl,Helena AU - Mouridsen,Henning AU - O'Malley,Frances P AU - Cardoso,Fatima AU - Tanner,Minna AU - Munro,Alison AU - Twelves,Chris J AU - Sotiriou,Christos AU - Shepherd,Lois AU - Cameron,David AU - Piccart,Martine J AU - Buyse,Marc TI - HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data SN - 1474-5488 PY - 2011///1221 KW - Anthracyclines KW - administration & dosage KW - Antigens, Neoplasm KW - genetics KW - Antineoplastic Combined Chemotherapy Protocols KW - therapeutic use KW - Biomarkers, Tumor KW - Breast Neoplasms KW - drug therapy KW - Chemotherapy, Adjuvant KW - Chi-Square Distribution KW - Clinical Trials, Phase III as Topic KW - DNA Topoisomerases, Type II KW - DNA-Binding Proteins KW - Disease-Free Survival KW - Evidence-Based Medicine KW - Female KW - Gene Amplification KW - Gene Deletion KW - Humans KW - In Situ Hybridization, Fluorescence KW - Kaplan-Meier Estimate KW - Middle Aged KW - Patient Selection KW - Poly-ADP-Ribose Binding Proteins KW - Precision Medicine KW - Predictive Value of Tests KW - Proportional Hazards Models KW - Randomized Controlled Trials as Topic KW - Receptor, ErbB-2 KW - Risk Assessment KW - Risk Factors KW - Survival Rate KW - Time Factors KW - Treatment Outcome N1 - Publication Type: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't UR - https://doi.org/10.1016/S1470-2045(11)70231-5 ER -